cryptotanshinone has been researched along with Cell Transformation, Neoplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, H; Kageyama, S; Kawauchi, A; Kim, CJ; Minami, K; Shirasawa, S; Tambe, Y; Tanaka, H; Terado, T; Tsunoda, T; Ushio, A | 1 |
| Chen, L; Wang, H; Wang, HJ; Xie, W; Yao, Y; Zhang, YS | 1 |
2 other study(ies) available for cryptotanshinone and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms; Glutamine; Humans; Lipids; Lipogenesis; Pancreatic Neoplasms; Phenanthrenes; Proto-Oncogene Proteins p21(ras); Reactive Oxygen Species; Signal Transduction | 2022 |
Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Body Weight; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Mice; Phenanthrenes; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |